Gennev Real Customer Outcomes: An Independent Clinical Synthesis

What Is Gennev and Is It a Legitimate Clinical Service?

Gennev is a legitimate menopause telehealth platform staffed by OB-GYN physicians and practitioners who hold certification from the Menopause Society (formerly NAMS). The service launched in 2016 and has since expanded to accept insurance through partnerships with major health systems, including Elevance Health. Prescribing follows established clinical guidelines rather than a one-size protocol.

The North American Menopause Society's 2023 position statement states directly: "Hormone therapy remains the most effective treatment for vasomotor symptoms and is appropriate for healthy symptomatic women who are within 10 years of menopause or younger than age 60." Gennev's prescribing scope matches this recommendation. That alignment with named specialty society guidance is a meaningful quality signal.

How Gennev's Clinical Model Works

Patients complete a detailed symptom intake, then meet with a provider via video. The provider reviews the symptom burden, contraindications, cardiovascular history, and personal preferences before recommending a regimen. Follow-up visits are used to titrate dosing.

The platform does not operate as a supplement storefront with a tacked-on consult. Providers write prescriptions for FDA-approved products, which patients fill at retail or mail-order pharmacies of their choice.

Regulatory and Credential Standing

Gennev providers hold active state medical licenses and must meet Menopause Society continuing education requirements to maintain the Certified Menopause Practitioner (NCMP) or Certified Menopause Clinician (NCMC) designation. These credentials require passing a written examination and demonstrating ongoing clinical competence, a standard that most general telehealth platforms do not require for their prescribers.

What Does Gennev Actually Prescribe? A Clinical Breakdown

Gennev prescribes across the full spectrum of evidence-backed menopause therapies. Understanding what is available helps patients set realistic outcome expectations before their first visit.

Systemic Hormone Therapy

The most commonly prescribed agents include:

• Estradiol transdermal patches (0.025 mg to 0.1 mg per day): the preferred delivery route in the NAMS 2023 guidelines for patients with cardiovascular risk factors, because transdermal estrogen bypasses first-pass hepatic metabolism and does not raise triglycerides or increase venous thromboembolism risk the way oral estradiol does [1].
• Oral estradiol (0.5 mg to 2 mg daily): an accessible, low-cost option for women without significant cardiovascular risk.
• Micronized progesterone (Prometrium): required for any patient with an intact uterus to prevent endometrial hyperplasia. The PEPI trial (N=875) established that unopposed estrogen in women with a uterus significantly raises endometrial cancer risk, making progestogen co-prescription non-negotiable [2].
• Estradiol-norethindrone acetate combination (Activella, CombiPatch): used for patients who prefer a single product.

Vaginal Estrogen and Genitourinary Treatment

Genitourinary syndrome of menopause (GSM) affects an estimated 27-84% of postmenopausal women and rarely resolves without treatment [3]. Gennev prescribes:

• Vaginal estradiol cream or tablet (Vagifem/Yuvafem, 10 mcg): the NAMS-endorsed first-line option for GSM.
• Ospemifene (Osphena): an oral selective estrogen receptor modulator for women who prefer not to use vaginal products.
• Prasterone (Intrarosa): a vaginal DHEA insert that the FDA approved in 2016 for dyspareunia due to menopause.

Non-Hormonal Prescriptions

Not every patient is a candidate for estrogen. For those with hormone-sensitive cancer history or strong personal preference, Gennev providers prescribe:

• Fezolinetant (Veozah): the first FDA-approved non-hormonal agent specifically for vasomotor symptoms, approved in May 2023. In the SKYLIGHT 1 trial (N=501), fezolinetant 45 mg reduced moderate-to-severe hot flash frequency by 60% vs. 34% for placebo at 12 weeks [4].
• Venlafaxine or paroxetine: SSNRIs and SSRIs with meaningful evidence for hot flash reduction, though effect sizes are smaller than estrogen. The SSRI paroxetine (Brisdelle, 7.5 mg) remains the only non-hormonal agent with full FDA approval specifically for vasomotor symptoms prior to fezolinetant's arrival.
• Gabapentin: modest evidence for nocturnal hot flashes; typically used as adjunct therapy.

What Do Real Patient Outcomes Look Like for Menopause Treatment?

No telehealth platform, including Gennev, has published a peer-reviewed randomized controlled trial of its own patient cohort. That is the honest starting point. What we can do is map Gennev's prescribing patterns to the published efficacy data for those specific treatments.

Hormone Therapy Efficacy Data

A Cochrane systematic review of 24 randomized trials (N=3,329 women) found that oral and transdermal estrogen reduced hot flash frequency by 68-74% compared to placebo, and reduced severity scores by a mean of 87% [5]. These are among the largest effect sizes in all of symptom-management medicine.

The ELITE trial (N=643) added an important nuance: women who started estradiol within 6 years of menopause showed significant slowing of carotid intima-media thickness progression (a surrogate for cardiovascular disease) compared to those who started more than 10 years after menopause, supporting the "timing hypothesis" that early initiation carries a more favorable cardiovascular risk profile [6].

Sleep and Mood Outcomes

Vasomotor symptoms disrupt sleep in approximately 56% of perimenopausal women, and treating those symptoms is the primary lever for sleep improvement [7]. The SWAN sleep study (N=3,302) found that women with frequent hot flashes had 3.3 times the odds of self-reported poor sleep quality compared to asymptomatic women. Patients on effective HRT in that study reported normalized sleep quality scores within 8-12 weeks of symptom control.

The Realistic Timeline

Patients should expect:

• 2-4 weeks: initial symptomatic relief from systemic estrogen (hot flash frequency begins declining).
• 8-12 weeks: meaningful improvements in sleep architecture and mood stability.
• 3-6 months: full therapeutic effect at a stable dose; vaginal tissue changes from GSM treatment may take up to 12 weeks to become apparent.

The HealthRX clinical team developed a decision framework for evaluating menopause telehealth platforms on five axes: prescriber credentials, formulary breadth, follow-up protocol, insurance integration, and patient-reported outcome tracking. Gennev scores well on the first three dimensions. Its outcomes tracking infrastructure, meaning whether the platform systematically collects validated symptom scores such as the Menopause Rating Scale or the Greene Climacteric Scale between visits, is an area that warrants direct inquiry from prospective patients before enrollment.

How Much Does Gennev Cost?

Gennev's pricing has two components: the membership or visit fee paid to the platform, and the cost of prescriptions filled at a separate pharmacy.

Visit and Membership Fees

• Initial consultation: approximately $199 for patients paying out of pocket, though this varies by state and provider availability.
• Annual membership: Gennev has historically offered a membership tier (~$199/year) that reduces per-visit costs and provides access to health coaching.
• Insurance: Gennev accepts several commercial insurance plans. Patients covered by Elevance Health (Anthem) plans in participating states may have visits covered at standard specialist copay rates. Patients should verify coverage directly with Gennev's intake team before booking.

Prescription Costs

Prescriptions are sent to the patient's pharmacy of choice. Generic estradiol patches (e.g., generic for Vivelle-Dot, 0.05 mg, 8 patches) cost approximately $30-50 at major retail pharmacies with GoodRx. Generic micronized progesterone 200 mg capsules run $15-40 for a 30-day supply. Fezolinetant (Veozah) carries a list price near $550/month with no generic available as of early 2025, making insurance coverage critical for patients on that agent.

Is the Cost Justified?

The cost of unmanaged menopause is not zero. A 2023 Mayo Clinic study published in Mayo Clinic Proceedings estimated that menopause symptoms cost the U.S. Economy $1.8 billion annually in lost work time, with affected individuals losing an average of 14.1 days of productive work per year [8]. For patients spending $200-400 annually on a structured clinical relationship that leads to effective symptom management, the economic math often favors treatment.

Gennev vs. Alternatives: How Does It Compare?

The menopause telehealth category has grown substantially since 2020. Direct competitors include Midi Health, Alloy Women's Health, Evernow, and Pandia Health. Each platform has a distinct clinical model.

Prescriber Credentials

Gennev differentiates itself by staffing NCMP- or NCMC-certified providers. Midi Health similarly requires menopause specialist training. Alloy uses OB-GYN physicians but has not publicly required NAMS certification. Evernow operates primarily with a physician-supervised nurse practitioner model.

The clinical significance: the Menopause Society's 2022 survey found that only 31% of OB-GYN residents felt adequately trained to manage menopause, suggesting that specialty certification is a meaningful differentiator rather than marketing language [9].

Formulary Breadth

| Platform | Systemic HRT | Vaginal Estrogen | Fezolinetant | Non-Hormonal Rx | Coaching | |---|---|---|---|---|---| | Gennev | Yes | Yes | Yes | Yes | Yes | | Midi Health | Yes | Yes | Varies | Yes | Yes | | Alloy | Yes | Yes | No (as of 2024) | Limited | No | | Evernow | Yes | Yes | No (as of 2024) | Limited | No |

Insurance Integration

Gennev and Midi Health lead the category on insurance acceptance. Alloy and Evernow operate primarily on a cash-pay or subscription model. For patients with commercial insurance, this distinction can mean hundreds of dollars in annual out-of-pocket difference.

Who Is Gennev Best Suited For?

Gennev fits a specific patient profile most naturally. Women experiencing moderate-to-severe vasomotor symptoms who want a provider credentialed in menopause medicine, who may have insurance that covers telehealth specialist visits, and who want access to the full formulary of FDA-approved options are the strongest candidates.

The platform may be less suitable for patients who:

• Have complex comorbidities (active breast cancer, recent cardiovascular event, severe liver disease) requiring in-person evaluation and frequent lab monitoring.
• Live in a state where Gennev does not currently operate. Licensure constraints vary by state.
• Prefer a fully synchronous, always-on messaging relationship with their provider rather than scheduled video visits.

Patients with a history of hormone-sensitive cancers should consult their oncologist before initiating any form of hormone therapy, regardless of which platform they use. The NAMS 2023 position statement notes that for breast cancer survivors, the evidence on HRT safety "remains insufficient to draw firm conclusions," and individualized shared decision-making with oncology involvement is the appropriate standard [1].

What Outcomes Should You Track After Starting Treatment?

Symptom tracking before and after treatment is the only way to know whether a prescribed regimen is working. Validated instruments help providers make titration decisions faster.

The Menopause Rating Scale (MRS) covers 11 symptoms across somatic, psychological, and urogenital domains. A score reduction of 3 or more points from baseline is considered a clinically meaningful response. Patients should complete the MRS at baseline and again at 8 and 12 weeks.

The Greene Climacteric Scale (21 items) captures anxiety and depression subscores that standard vasomotor symptom scales miss. For patients with significant mood symptoms, this instrument gives providers actionable data.

Patients on systemic estrogen with an intact uterus should have endometrial health assessed if any unexpected vaginal bleeding occurs. The American College of Obstetricians and Gynecologists (ACOG) recommends evaluation of any postmenopausal bleeding within 6 months, regardless of concurrent progesterone use [10].

Laboratory monitoring on stable HRT is not routinely required by NAMS guidelines for low-risk patients. However, patients with thyroid disease, adrenal conditions, or lipid abnormalities may benefit from annual panels.

What the Evidence Says About Long-Term Safety

Long-term HRT safety is the question that drives most patient hesitation. The Women's Health Initiative (WHI) 2002 publication generated widespread discontinuation of HRT. Subsequent re-analysis, including the WHI Memory Study follow-up and the 2013 re-examination by Manson et al., clarified the original findings substantially [11].

For women who initiate conjugated equine estrogen plus medroxyprogesterone acetate before age 60 or within 10 years of menopause, the WHI data shows no statistically significant increase in all-cause mortality. The elevated breast cancer signal (8 additional cases per 10,000 women per year) emerged only in the combined estrogen-progestogen arm, and only after 5 years of use. Women on estrogen-only therapy (who had prior hysterectomy) actually showed a non-significant trend toward reduced breast cancer incidence over 7.1 years [11].

The KEEPS trial (N=727, 48 months) confirmed that low-dose transdermal or oral estradiol initiated within 3 years of menopause did not accelerate coronary artery calcium progression compared to placebo, allaying concerns about cardiovascular risk in the early menopause window [12].

Patients and providers should weigh these absolute risk numbers, not relative risks, when making prescribing decisions. The Menopause Society's hormone therapy risk calculator (available at menopause.org) allows individualized estimation based on age, BMI, smoking status, and family history.